Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) was the target of a large growth in short interest in the month of April. As of April 30th, there was short interest totaling 523,399 shares, a growth of 363.6% from the April 15th total of 112,896 shares. Based on an average daily volume of 4,873,175 shares, the days-to-cover ratio is currently 0.1 days. Currently, 6.0% of the company’s shares are sold short.
Cumberland Pharmaceuticals Stock Down 0.9%
CPIX opened at $4.53 on Wednesday. Cumberland Pharmaceuticals has a fifty-two week low of $1.85 and a fifty-two week high of $6.26. The business has a 50-day moving average of $3.49 and a 200-day moving average of $3.46. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.95 and a quick ratio of 0.84. The company has a market capitalization of $67.86 million, a PE ratio of -9.24 and a beta of -0.06.
Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.The company had revenue of $9.13 million during the quarter, compared to the consensus estimate of $8.50 million.
Institutional Investors Weigh In On Cumberland Pharmaceuticals
Analyst Ratings Changes
A number of research firms recently weighed in on CPIX. Wall Street Zen upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Cumberland Pharmaceuticals currently has a consensus rating of “Sell”.
View Our Latest Research Report on CPIX
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.
The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.
Read More
- Five stocks we like better than Cumberland Pharmaceuticals
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
